| Hazard Information | Back Directory | [Uses]
Lumasiran sodium, an investigational RNA interference (RNAi) therapeutic agent, reduces hepatic oxalate production by targeting glycolate oxidase. Lumasiran sodium reduces urinary oxalate excretion, the cause of progressive kidney failure in primary hyperoxaluria type 1 (PH1) [1][2]. | [in vivo]
Lumasiran sodium is a subcutaneously administered, liver-directed RNA interference (RNAi) therapeutic agent[2]. | [References]
[1] Scott LJ, et al. Lumasiran: First Approval. Drugs. 2021;81(2):277-282. DOI:10.1007/s40265-020-01463-0
[2] Garrelfs SF, et al. Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1. N Engl J Med. 2021 Apr 1;384(13):1216-1226. DOI:10.1056/NEJMoa2021712 |
|
| Company Name: |
Ribobay Gold
|
| Tel: |
(86) 0550-5361572 13958538646 |
| Website: |
www.ribobay.com/en/ |
|